Zafgen Revenue and Competitors
Estimated Revenue & Valuation
- Zafgen's estimated annual revenue is currently $7.5M per year. 0
- Zafgen's total funding is $250.2M.
Employee Data
- 00
Zafgen Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Zafgen?
Zafgen Inc. is the first biopharmaceutical company dedicated to developing novel obesity therapeutics based on vascular targeting in adipose tissue (fat). Unique among all tissues in the human body, adipose is exceptional for its capacity to expand and contract based upon nutritional and metabolic factors. This plasticity is dependent upon the ability of adipose tissue to remodel and grow new blood vessels. Zafgen’s groundbreaking approach directly targets the plasticity of adipose vasculature in order to shrink fat cells and help the body sustain a lean, healthy state. Zafgen’s leadership and scientific advisors include the leading experts in obesity, metabolic disorders and medicinal chemistry. Founded in 2005, the company is located in Cambridge, Massachusetts. Corporate Profile Investors
keywords:Biotechnology
$250.2M
Total Funding
N/A
Number of Employees
$7.5M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Zafgen News
... Alizyme, BoehringerIngelheim GmbH, Pfizer, Takeda Pharmaceutical, Rhythm Pharmaceuticals, Shionogi USA, Vivus, Zafgen, Norgine Pharmaceuticals Ltd.
... And Forecast | Asieris Pharmaceuticals Co Ltd, Chong Kun Dang Pharmaceutical Corp, Merck KGaA, SynDevRx Inc, Takeda Pharmaceutical Co Ltd, Zafgen Inc.
ZappRx will also work with obesity-focused biopharma company Zafgen (NASDAQ: ZFGN), to support patients with Prader-Willi syndrome — a genetic condition affecting up to 30,000 people — and hypothalamic injury-associated obesity. Promoted This Patient Experience Checklist Is Your Key To Success ...
Instead of suppressing hunger, Zafgen’s obesity drug beloranib, inhibits the enzyme methionine aminopeptidase 2 and makes the body produce less fat and burn off the excess as fuel. Because the effects of the drug don’t appear to impact the brain in the way previous weight-loss drugs like fen-phe ...
Zafgen, Inc., a Cambridge, MA-based biopharmaceutical company, closed a $20m term loan. Oxford Finance and MidCap Financial provided the loan. The company intends to use the proceeds for working capital growth. Founded in 2005, Zafgen develops Beloranib, a twice-weekly subcutaneous injection ...
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $77M | 0 | N/A | $866M |
#2 | $7.4M | 0 | N/A | $0.5M |
#3 | $5.5M | 0 | N/A | $86.3M |
#4 | $17.4M | 0 | N/A | $194.3M |
#5 | $66.9M | 0 | N/A | $142M |